Harvard's Christopher P. Cannon, MD -- On Anacetrapib, And DEFINE's Meaning

. . . . Primary Results of the DEFINE trial: Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib.
. . .

I suppose I should label this the "equal time" portion of our broadcast -- to pair it off, with Ms. Mendes' silly clip, much below.

More seriously, the key points here are the unknowns, as even Dr. Cannon candidly volunteers. Will the results be borne out in the 30,000 patient trial? And if so, when? We shall see.